TP53 and neoplasm: However, TP53-null fibroblasts sensitize tumor cells to chemotherapeutic agents, such as doxorubicin and cisplatin (Lafkas et al., 2008), and radiotherapy (Burdelya et al., 2006), indicating that stromal TP53 also influences the response to therapy.